ライフサイエンスコーパス: pemetrexed

1 50 = 120 nM, about 55-fold more potent than pemetrexed).

2 t Panel recommends pembrolizumab/carboplatin/pemetrexed.

3 of ADI-PEG20 activity by the antifolate drug pemetrexed.

4 These cells were cross-resistant to pemetrexed.

5 vival outcomes as compared with single-agent pemetrexed.

6 ms that predict for survival and toxicity of pemetrexed.

7 he transport and pharmacological activity of pemetrexed.

8 ures predicting sensitivity to cisplatin and pemetrexed.

9 hibitory activity with the chemotherapy drug pemetrexed.

10 folate metabolism, such as methotrexate and pemetrexed.

11 received gemcitabine, and 497 (33%) received pemetrexed.

12 d cisplatin and pemetrexed or paclitaxel and pemetrexed.

13 nds are cleaved, resulting in the release of pemetrexed.

14 ion of apricoxib to second-line docetaxel or pemetrexed.

15 95% CI, 0.64 to 0.96; P = .0195; median OS: pemetrexed, 13.9 months; placebo, 11.0 months).

16 ss frequent in elderly patients treated with pemetrexed (2.5%) compared with docetaxel (19%; P = .025

17 Of the remaining 938 patients, 605 received pemetrexed (301 patients with cetuximab and 304 alone) a

18 ment occurred along with a rapid adoption of pemetrexed (39.2%), erlotinib (20.3%), and bevacizumab (

19 y of carboplatin area under the curve 5 with pemetrexed 500 mg/m(2) administered intravenously on day

20 Gef) or gefitinib 250 mg orally per day plus pemetrexed 500 mg/m(2) and carboplatin area under curve

21 2), 27 mg/m(2), or 36 mg/m(2), together with pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) which we

22 ed seventy-one patients received intravenous pemetrexed 500 mg/m(2) day 1 and oral ABT-751 or placebo

23 oplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrol

24 nts received either cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 of a 3-week cycle for a

25 citabine 1,250 mg/m(2) on days 1 and 8, with pemetrexed 500 mg/m(2) on day 1.

26 citabine 1,250 mg/m(2) on days 1 and 8, with pemetrexed 500 mg/m(2) on day 8, and cohort 2 received g

27 ublet chemotherapy cisplatin 75 mg/m(2) plus pemetrexed 500 mg/m(2) on the first day of each cycle.

28 Docetaxel 75 mg/m(2) or pemetrexed 500 mg/m(2) once every 21 days per the invest

29 umab 7.5 mg/kg or bevacizumab 7.5 mg/kg plus pemetrexed 500 mg/m(2) once every 3 weeks until disease

30 eatment cycles) or chemotherapy (intravenous pemetrexed 500 mg/m(2) or docetaxel 75 mg/m(2) [investig

31 of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combine

32 Patients received pemetrexed 500 mg/m(2) plus cisplatin 75 mg/m(2) for fou

33 otinib (150 mg/day, orally) or chemotherapy (pemetrexed 500 mg/m(2), intravenously, every 21 days, or

34 ) plus three-weekly cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2).

35 latin 75 mg/m(2) or carboplatin AUC 5-6 plus pemetrexed 500 mg/m(2)] every 3 weeks for four cycles fo

36 s randomly assigned to docetaxel 75 mg/m2 or pemetrexed 500 mg/m2 every 3 weeks were analyzed for eff

37 Patients received pemetrexed 500 mg/m2 intravenously on day 1 every 21 day

38 aily or intravenous chemotherapy with either pemetrexed (500 mg per square meter of body-surface area

39 ock and Simon minimisation method to receive pemetrexed (500 mg/m(2) every 21 days; n=441) or placebo

40 were randomly assigned (2:1) to maintenance pemetrexed (500 mg/m(2) on day 1 of 21-day cycles; n = 3

41 mcitabine (1200 mg/m(2) on days 1 and 8), or pemetrexed (500 mg/m(2) on day 1).

42 ression, patients in all three arms received pemetrexed (500 mg/m(2) once every 21 days) as predefine

43 nts were randomly assigned to receive either pemetrexed (500 mg/m(2)) or docetaxel (75 mg/m(2)) and t

44 system to receive up to six 21-day cycles of pemetrexed (500 mg/m(2)) plus cisplatin (75 mg/m(2)) on

45 patients received four cycles of intravenous pemetrexed (500 mg/m(2)) with carboplatin (5 mg/mL per m

46 tenance therapy with bevacizumab (15 mg/kg), pemetrexed (500 mg/m(2)), or a combination of the two ag

47 With vitamin supplementation, pemetrexed 600 mg/m2 was tolerated by patients with a GF

48 Postdiscontinuation therapy use was similar: pemetrexed, 64%; placebo, 72%.

49 After 397 deaths (pemetrexed, 71%; placebo, 78%) and a median follow-up of

50 b and 116 (50%) to chemotherapy (40 [34%] to pemetrexed, 73 [63%] to docetaxel, and three [3%] discon

51 ctor (VEGF), will potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell

52 n tumors, and the ability of PCFT to sustain pemetrexed activity even in the absence of RFC, tumor ce

53 CFT and RFC produced comparable increases in pemetrexed activity in growth medium with 5-formyltetrah

54 We suggest that the activity of pemetrexed against human cancers is a reflection of its

55 Pemetrexed (ALIMTA, Lilly) is a folate antimetabolite th

56 ce therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maint

57 ith five (2%) of 289 treated patients in the pemetrexed alone group.

58 reased neutrophil count (28 [10%]), and with pemetrexed alone were dyspnoea (35 [12%] of 289 patients

59 t to require AMPKalpha T172 phosphorylation, pemetrexed also activated AMPK in carcinoma cells null f

60 with three clinically prevalent antifolates, pemetrexed (also Alimta), aminopterin, and methotrexate.

61 The chemotherapeutic drug pemetrexed, an inhibitor of thymidylate synthase, has an

62 stent with FR-mediated transport, subsequent pemetrexed and (6S)-5-formyltetrahydrofolate export into

63 enance cycles was 7.9 (range, one to 44) for pemetrexed and 5.0 (range, one to 38) for placebo.

64 tin, and bevacizumab followed by maintenance pemetrexed and bevacizumab in patients with chemotherapy

65 o [HR], 0.86; P = .12); median survival with pemetrexed and bevacizumab was 16.4 months (HR, 0.9; P =

66 or patients with response or stable disease, pemetrexed and bevacizumab were continued until disease

67 Adding pemetrexed and carboplatin chemotherapy to an oral tyros

68 Adding pemetrexed and carboplatin chemotherapy to gefitinib sig

69 bocytopenia (13.2% v 22.9%) in the cisplatin/pemetrexed and carboplatin/pemetrexed treatment groups,

70 patients to receive either necitumumab plus pemetrexed and cisplatin (n=315) or pemetrexed and cispl

71 mab plus pemetrexed and cisplatin (n=315) or pemetrexed and cisplatin alone (n=318).

72 ] of 304 vs one [<1%] of 312 patients in the pemetrexed and cisplatin alone group), hypomagnesaemia (

73 ] vs 11 [4%] patients) than did those in the pemetrexed and cisplatin alone group.

74 citumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin alone in patients with previous

75 The median number of pemetrexed and cisplatin cycles was six; the median trea

76 oves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of pat

77 s pemetrexed and cisplatin group than in the pemetrexed and cisplatin group (155 [51%] of 304 vs 127

78 group versus 11.5 months (10.1-13.1) in the pemetrexed and cisplatin group (hazard ratio 1.01 [95% C

79 Patients in the necitumumab plus pemetrexed and cisplatin group had more grade 3-4 rash (

80 kewise more frequent in the necitumumab plus pemetrexed and cisplatin group than in the pemetrexed an

81 g deaths, was higher in the necitumumab plus pemetrexed and cisplatin group than in the pemetrexed an

82 hs (95% CI 9.5-13.4) in the necitumumab plus pemetrexed and cisplatin group versus 11.5 months (10.1-

83 roup versus nine (3%) of 312 patients in the pemetrexed and cisplatin group.

84 s pemetrexed and cisplatin group than in the pemetrexed and cisplatin group; in particular, deaths re

85 suggest that the addition of necitumumab to pemetrexed and cisplatin increases survival of previousl

86 signed in a 1:1 ratio to up to six cycles of pemetrexed and cisplatin plus nintedanib (200 mg twice d

87 We aimed to compare necitumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin a

88 n this patient population when combined with pemetrexed and cisplatin.

89 semblies are prepared by co-assembly between pemetrexed and cytosine-containing diselenide through hy

90 nase inhibitor) than with the combination of pemetrexed and either cisplatin or carboplatin (platinum

91 , switch maintenance therapy strategies with pemetrexed and erlotinib have demonstrated improved over

92 Pemetrexed and gemcitabine are synergistic in preclinica

93 Pemetrexed and gemcitabine have single-agent activity in

94 rongly suggest that combination therapy with pemetrexed and gemcitabine is a promising treatment for

95 We found that pemetrexed and gemcitabine preferentially inhibited G3 M

96 The combination of pemetrexed and gemcitabine resulted in moderate clinical

97 times are similar to those with single-agent pemetrexed and inferior to outcomes observed with cispla

98 Thymidylate synthase (TS) is a target for pemetrexed and the prodrug 5-fluorouracil (5-FU) that in

99 erstand the role of autophagy in response to pemetrexed and to test if combination therapy could enha

100 nt to which PCFT contributes to transport of pemetrexed and to the activities of this and other antif

101 50 = 46 nM, about 206-fold more potent than pemetrexed) and DHFR (IC 50 = 120 nM, about 55-fold more

102 rapy; 22 of 39 second-line patients received pemetrexed, and nine of 39 received erlotinib.

103 37%, and 51%, respectively, for bevacizumab, pemetrexed, and the combination regimen.

104 Pemetrexed, approved for the treatment of non-small cell

105 gnificantly improved in the bevacizumab plus pemetrexed arm (median, 3.7 v 7.4 months; hazard ratio,

106 motherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B

107 or cells are unlikely to become resistant to pemetrexed as a result of impaired transport because of

108 ranslation and lipid metabolism, identifying pemetrexed as a targeted therapeutic agent for this path

109 anistic rationale for combining GMX1777 with pemetrexed as an effective new therapeutic strategy to t

110 s in both arms received up to four cycles of pemetrexed as consolidation therapy.

111 and efficacy of bevacizumab with or without pemetrexed as continuation maintenance treatment.

112 Combination of Gli-I and pemetrexed, as well as Gli-I and vismodegib demonstrated

113 Herein, we develop diselenide-pemetrexed assemblies that combine natural killer (NK) c

114 Pemetrexed at a dose of 900 mg/m(2) was to be administer

115 nt options include pembrolizumab/carboplatin/pemetrexed, atezolizumab/carboplatin/paclitaxel/bevacizu

116 New compounds such as pemetrexed, bortezomib, TLK286, bevacizumab, and the epo

117 increased the growth inhibitory activity of pemetrexed, but not that of the other antifolates in Hep

118 omic predictors of response to cisplatin and pemetrexed can be incorporated into strategies to optimi

119 toxicity, the combination of bevacizumab and pemetrexed cannot be recommended.

120 PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With

121 s study evaluated the efficacy and safety of pemetrexed, carboplatin, and bevacizumab followed by mai

122 The combination of pemetrexed, carboplatin, and TRT met the prespecified cr

123 onse rates were also significantly lower for pemetrexed-carboplatin (31% v 52%; P < .001).

124 le between arms and anemia was higher in the pemetrexed-carboplatin arm.

125 Pemetrexed-carboplatin had lower grade 3 to 4 neutropeni

126 Pemetrexed-carboplatin is inferior for the treatment of

127 objective of the study was noninferiority of pemetrexed-carboplatin overall survival with a 15% margi

128 In the final analysis, pemetrexed-carboplatin was inferior to etoposide-carbopl

129 , a phase III study was conducted to compare pemetrexed-carboplatin with etoposide-carboplatin for th

130 /kg plus gemcitabine-cisplatin (squamous) or pemetrexed-cisplatin (nonsquamous) or nivolumab 5 or 10

131 1 ratio to receive afatinib or chemotherapy (pemetrexed-cisplatin [LUX-Lung 3] or gemcitabine-cisplat

132 nib group and 28.2 months (20.7-33.2) in the pemetrexed-cisplatin group (HR 0.88, 95% CI 0.66-1.17, p

133 rformance status who did not progress during pemetrexed-cisplatin induction therapy.

134 lung cancer (NSCLC) received four cycles of pemetrexed-cisplatin induction therapy; then, 539 patien

135 mcitabine-cisplatin, nivolumab 10 mg/kg plus pemetrexed-cisplatin, nivolumab 10 mg/kg plus paclitaxel

136 , the in vitro enzyme velocity at saturating pemetrexed concentrations was reduced by 1.6-fold (R424C

137 ith stable disease or response to first-line pemetrexed-containing regimens, alternative chemotherapy

138 Maintenance therapy includes pemetrexed continuation for patients with stable disease

139 Pemetrexed continuation maintenance therapy is well-tole

140 In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the

141 mbination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-lin

142 four standard-dose courses of cisplatin plus pemetrexed (CP).

143 overall survival seem comparable to that of pemetrexed, docetaxel, and erlotinib in similar groups o

144 hibited this effect, impairing cell death by pemetrexed either alone or in combination with GMX1777.

145 Twenty-six patients received pemetrexed (either alone or in combination with platinum

146 as determined by histology: carboplatin plus pemetrexed for nonsquamous NSCLC and carboplatin plus ge

147 include docetaxel, erlotinib, gefitinib, or pemetrexed for patients with nonsquamous cell carcinoma;

148 eks for four cycles, followed by maintenance pemetrexed (gefitinib plus chemotherapy [Gef+C]).

149 The combination of pemetrexed/gemcitabine has not previously been studied i

150 proportion of patients in the cetuximab plus pemetrexed group (119 [41%] of 292 patients) experienced

151 ous adverse event than those patients in the pemetrexed group (85 [29%] of 289 patients; p=0.0054).

152 of 292 treated patients in the cetuximab and pemetrexed group died of adverse events compared with fi

153 greater increase in loss of appetite in the pemetrexed group than in the placebo group (4.3 mm vs 0.

154 ulted in substantial raltitrexed, but modest pemetrexed, growth inhibition consistent with their affi

155 ifolates (relative affinities: raltitrexed > pemetrexed > MTX) at low pH.

156 Elderly patients treated with pemetrexed had a longer time to progression and a longer

157 ents who received bevacizumab, erlotinib, or pemetrexed had the longest treatment durations on averag

158 The combination of bevacizumab and pemetrexed has also demonstrated efficacy.

159 Pemetrexed has more than one site of action; the primary

160 Pemetrexed has sufficient activity in the treatment of r

161 Switch-maintenance trials with erlotinib and pemetrexed have demonstrated an improvement in overall s

162 axel, erlotinib, gefitinib, gemcitabine, and pemetrexed have evaluated outcomes in patients who recei

163 Newer agents, such as pemetrexed, have shown significant activity as second-li

164 CI 2.7-3.2) versus 2.8 months (2.5-3.3) with pemetrexed (HR 1.03, 95% CI 0.87-1.21; p=0.76).

165 t improved by the addition of carboplatin to pemetrexed (HR, 90; 95% CI, 0.74 to 1.10; P = .316; P he

166 The addition of cediranib to platinum-pemetrexed improved PFS by RECIST v1.1 and response rate

167 , pharmacokinetics, and recommended doses of pemetrexed in cancer patients with normal and impaired r

168 es (DLTs), and pharmacokinetic properties of pemetrexed in children.

169 Pemetrexed in combination with cisplatin demonstrates ac

170 Pemetrexed in combination with cisplatin is approved for

171 Hence, resistance to pemetrexed in M160-8 cells was due to entrapment of the

172 d tolerability of ADI-PEG 20, cisplatin, and pemetrexed in patients with ASS1-deficient malignant ple

173 ternative, single-agent chemotherapy such as pemetrexed in patients with nonsquamous histology, docet

174 oup analyses, the addition of carboplatin to pemetrexed in patients with squamous tumors led to a sta

175 to assess the impact of carboplatin added to pemetrexed in terms of overall survival (OS).

176 rexed susceptibility phenotype variation for pemetrexed in the discovery population.

177 othelial tissues and the differences between pemetrexed-induced senescence and that induced by the re

178 strate concentrations (~2.5 muM), only [(3)H]pemetrexed influx [in contrast to methotrexate (MTX), fo

179 The pemetrexed influx K(m) was ~300 muM; the raltitrexed inf

180 At 300 muM MTX, influx was one-third that of pemetrexed; influx of folic acid, (6S)5-methyltetrahydro

181 AICART reaction, ZMP, accumulated in intact pemetrexed-inhibited tumor cells, identifying AICART as

182 ur findings indicate that AMPK activation by pemetrexed inhibits mTORC1-dependent and -independent pr

183 he recommended phase II dose of ABT-751 with pemetrexed is 200 mg.

184 Pemetrexed is a multitargeted antifolate with manageable

185 Pemetrexed is a novel antifolate that inhibits multiple

186 Carboplatin/pemetrexed is a well-tolerated regimen with activity in

187 Pemetrexed is an inhibitor of dihydrofolate reductase cu

188 Single-agent bevacizumab or pemetrexed is efficacious as maintenance therapy for adv

189 Pemetrexed is known to activate PARPs, thereby accelerat

190 Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy.

191 mmended; in patients with nonsquamous NSCLC, pemetrexed is recommended.

192 eling of the licensed agents bevacizumab and pemetrexed is restricted to patients with nonsquamous ce

193 Single-agent pemetrexed is safe and active as second-line treatment o

194 lity of life during maintenance therapy with pemetrexed is similar to placebo, except for a small inc

195 Pemetrexed is well-tolerated in children with refractory

196 Addition of ABT-751 to pemetrexed is well-tolerated, but does not improve outco

197 a phase I trial and pharmacokinetic study of pemetrexed (LY231514) in children and adolescents with r

198 ) every 3 weeks for four cycles, followed by pemetrexed maintenance therapy every 3 weeks.

199 y pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carbopl

200 Pemetrexed maintenance therapy significantly improved ov

201 all and progression-free survival noted with pemetrexed maintenance therapy, such treatment is an opt

202 and pemetrexed alone followed by indefinite pemetrexed maintenance therapy.

203 motherapy plus bevacizumab, bevacizumab plus pemetrexed maintenance was associated with a significant

204 ts occurred more often with bevacizumab plus pemetrexed maintenance.

205 Antifolates currently in the clinic, such as pemetrexed, methotrexate, and pralatrexate, are transpor

206 l and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative patients (HR, 0.99

207 el and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months for ERCC1-positive patients (HR, 1.11

208 d whether the indirect activation of AMPK by pemetrexed offers an effective therapeutic strategy for

209 rvival with cetuximab plus pemetrexed versus pemetrexed, on an intention-to-treat basis.

210 Pemetrexed or bevacizumab is used for maintenance therap

211 e, investigators chose whether to treat with pemetrexed or docetaxel on a patient-by-patient basis.

212 nonsquamous patients received cisplatin and pemetrexed or paclitaxel and pemetrexed.

213 ival (OS); patients who received second-line pemetrexed or with a performance status of 0 appeared to

214 zumab with either chemotherapy (docetaxel or pemetrexed) or erlotinib and preliminarily assessed thes

215 Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (

216 Pemetrexed plasma and urine pharmacokinetics were evalua

217 Pemetrexed plasma clearance positively correlated with G

218 % CI -1.3 to 3.2] increase) and placebo plus pemetrexed-platinum (-2.6 points [-5.8 to 0.5] decrease;

219 1.2 to 3.6] increase) than with placebo plus pemetrexed-platinum (-4.0 points [-7.7 to -0.3] decrease

220 4.8 months to not reached) with placebo plus pemetrexed-platinum (hazard ratio 0.81 [95% CI 0.60-1.09

221 were maintained with both pembrolizumab plus pemetrexed-platinum (least-squares mean change: 1.0 poin

222 re better maintained with pembrolizumab plus pemetrexed-platinum (least-squares mean change: 1.3 poin

223 ta further support use of pembrolizumab plus pemetrexed-platinum as first-line therapy for patients w

224 Following a phase II trial in which pemetrexed-platinum demonstrated similar activity to tha

225 %) of 402 patients in the pembrolizumab plus pemetrexed-platinum group and 180 (90%) of 200 in the pl

226 %) of 405 patients in the pembrolizumab plus pemetrexed-platinum group and 200 (99%) of 202 patients

227 oup and 180 (90%) of 200 in the placebo plus pemetrexed-platinum group were compliant with QLQ-C30; a

228 mplete or partial response over placebo plus pemetrexed-platinum in the KEYNOTE-189 study.

229 Pembrolizumab plus pemetrexed-platinum led to superior overall survival and

230 nths to not reached) with pembrolizumab plus pemetrexed-platinum, and was 7.0 months (4.8 months to n

231 00 (99%) of 202 patients in the placebo plus pemetrexed-platinum-treated group completed at least one

232 Pemetrexed/platinum doublets had activity and appeared t

233 eived maintenance until disease progression: pemetrexed plus bevacizumab (for the PemCBev group) or b

234 latin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (P

235 ly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B).

236 Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival ou

237 eived pemetrexed plus cisplatin, 18 received pemetrexed plus carboplatin, and four received a combina

238 ed to investigate the efficacy and safety of pemetrexed plus cisplatin combined with nintedanib or pl

239 ed that trimodality therapy with neoadjuvant pemetrexed plus cisplatin is feasible with a reasonable

240 Conclusion Addition of nintedanib to pemetrexed plus cisplatin resulted in PFS improvement.

241 Neoadjuvant pemetrexed plus cisplatin was administered, followed by

242 A total of 26 patients received pemetrexed plus cisplatin, 18 received pemetrexed plus c

243 inical study assessed safety and efficacy of pemetrexed plus gemcitabine in chemotherapy-naive patien

244 The combination of pemetrexed plus gemcitabine was active in patients with

245 brids of the clinically used anticancer drug pemetrexed (PMX) and our 6-substituted thiopheneyl pyrro

246 Compound 2 and pemetrexed (Pmx) competed with [(3)H]methotrexate for PC

247 Both 1 and pemetrexed (Pmx) inhibited proliferation of R1-11-PCFT4

248 Pemetrexed (PMX) is a 5-substituted pyrrolo[2,3-d]pyrimi

249 Pemetrexed pretreatment inhibited biotinylation of TMD2

250 In this subset, pemetrexed produced a more favorable toxicity profile.

251 Methotrexate (MTX) and pemetrexed (PTX) are two examples of antifolates that ha

252 bition of purine synthesis by the antifolate pemetrexed (PTX), a drug used extensively in the treatme

253 eeks for four cycles followed by maintenance pemetrexed); randomisation was stratified by World Healt

254 While pemetrexed rapidly associated with FR and was internaliz

255 the IC(50) values for both methotrexate and pemetrexed relative to the WT Cyt form of FPGS.

256 Like rapamycin analogs, pemetrexed relieved feedback suppression of PI3K and AKT

257 Pemetrexed represents the first antifolate cancer drug t

258 tly, between the likelihood of cisplatin and pemetrexed response in patients.

259 y aimed at identifying genetic predictors of pemetrexed response.

260 The addition of bevacizumab to pemetrexed resulted in promising efficacy outcomes in SC

261 Genomic-derived signatures of cisplatin and pemetrexed sensitivity were shown to accurately predict

262 tion was seen between in vitro cisplatin and pemetrexed sensitivity, and importantly, between the lik

263 and severe pulmonary hemorrhage, whereas for pemetrexed, superior treatment effects have been observe

264 ioblastoma, the combination of sorafenib and pemetrexed suppressed tumor growth without deleterious e

265 3 expression signature explained >30% of the pemetrexed susceptibility phenotype variation for pemetr

266 into the observed genetic associations with pemetrexed susceptibility.

267 f resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for

268 is (HR 0.58, 95% CI 0.34-0.97; p=0.038) with pemetrexed than with placebo; no other significant diffe

269 of BNC tumor-bearing mice with cisplatin and pemetrexed, the current frontline treatment, prolongs su

270 e so when used in combination with cisplatin+pemetrexed, the current standard of care.

271 n predictors of susceptibility phenotype for pemetrexed, the work presented here will be valuable to

272 live patients (95% CI, 23.2 to 25.1 months), pemetrexed therapy resulted in a statistically significa

273 cted in a greater than additive fashion with pemetrexed to increase autophagy and to kill a diverse a

274 glutamation of folic acid, methotrexate, and pemetrexed to produce highly active metabolites.

275 motherapeutic response to both cisplatin and pemetrexed to provide a rational approach to effective i

276 Polymorphisms in genes responsible for pemetrexed transport (reduced folate carrier [SLC19A1])

277 Activation of AMPK by ZMP in pemetrexed-treated colon and lung carcinoma cells and th

278 and neutropenia were significantly higher in pemetrexed-treated patients.

279 in the cisplatin/pemetrexed and carboplatin/pemetrexed treatment groups, respectively.

280 ounteracting the increase of OCT4 induced by pemetrexed treatment which is known to favor the develop

281 ingle-agent bevacizumab and bevacizumab plus pemetrexed treatment, respectively.

282 nogenicity, cell migration and resistance to pemetrexed treatment.

283 rogression-free survival with cetuximab plus pemetrexed versus pemetrexed, on an intention-to-treat b

284 CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) month

285 Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months

286 The MST for carboplatin/pemetrexed was 10.4 months, with a 1-year survivorship o

287 llow-up of 50.6 months, median survival with pemetrexed was 15.9 months, compared with 14.4 months wi

288 rogression-free survival with cetuximab plus pemetrexed was 2.9 months (95% CI 2.7-3.2) versus 2.8 mo

289 Median survival time (MST) for cisplatin/pemetrexed was 7.6 months, with a 1-year survivorship of

290 Pemetrexed was administered as a 10-minute intravenous i

291 Survival on pemetrexed was consistently improved for all patient sub

292 Recently, continuation maintenance with pemetrexed was found to prolong overall survival as well

293 Treatment with carboplatin plus pemetrexed was initiated, without bevacizumab because of

294 Pemetrexed was well tolerated at doses of 500 mg/m2 with

295 es (median, four; range one to 19 cycles) of pemetrexed were administered, with 40% of patients recei

296 grade 3-4 adverse events with cetuximab plus pemetrexed were fatigue (33 [11%] of 292 patients), acne

297 nd randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recu

298 We found that combining pemetrexed with GMX1777 produced a synergistic therapeut

299 ally impaired patients receiving higher dose pemetrexed with vitamin supplementation.

300 t HepG2 cells, exhibited a high affinity for pemetrexed, with an influx K(m) value of 0.2 to 0.8 muM